Kandi Arwine
Family · Garden City, KSNPI 1801319181
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,532, 3.6 times the $421 reported in 2021. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$460
- GSK$354
- Genentech USA, Inc.$314
- Sanofi$283
- Bristol Myers Squibb$270
- Merck$269
- plus $4K from 54 others
Across 1 payment — averaging $6000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$6K
What the payments were for
- Food & beverage$6,02399%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,098 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 34 | $621 |
| Letrozole | 27 | $607 |
| Acyclovir | 22 | $503 |
| Oxycodone Hcl | 15 | $419 |
| Prochlorperazine Maleate | 29 | $365 |
| Levothyroxine Sodium | 37 | $292 |
| Hydroxyurea | 13 | $286 |
| Anastrozole | 26 | $251 |
| Tamoxifen Citrate | 11 | $197 |
| Potassium Chloride | 26 | $174 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $87 |
| Gabapentin | 16 | $70 |
| Alendronate Sodium | 16 | $66 |
| Allopurinol | 14 | $39 |
Paid to pharmacies, not to this prescriber.
Other family in Garden City
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.